Cantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "overweight" rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Monday,Benzinga reports. They presently have a $65.00 target price on the stock. Cantor Fitzgerald's price target suggests a potential upside of 197.21% from the company's current price.

Other equities research analysts have also issued research reports about the stock. JMP Securities restated a "market outperform" rating and set a $89.00 price target on shares of Structure Therapeutics in a research note on Monday. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright decreased their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Citigroup assumed coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $76.17.

Structure Therapeutics Trading Up 0.6%

Shares of NASDAQ:GPCR traded up $0.14 during mid-day trading on Monday, hitting $21.87. 425,460 shares of the company traded hands, compared to its average volume of 848,973. The stock has a 50-day moving average price of $23.26 and a two-hundred day moving average price of $24.14. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $47.48. The stock has a market cap of $1.25 billion, a P/E ratio of -25.23 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Principal Financial Group Inc. grew its position in Structure Therapeutics by 45.1% in the fourth quarter. Principal Financial Group Inc. now owns 791,134 shares of the company's stock worth $21,456,000 after acquiring an additional 245,775 shares during the period. Handelsbanken Fonder AB acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth about $4,475,000. Jones Financial Companies Lllp raised its position in Structure Therapeutics by 29.8% in the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock valued at $115,000 after purchasing an additional 971 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after purchasing an additional 953 shares during the period. Finally, M&T Bank Corp increased its position in Structure Therapeutics by 100.0% during the 4th quarter. M&T Bank Corp now owns 18,110 shares of the company's stock worth $492,000 after purchasing an additional 9,055 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.